We would particularly note that in this case the UPC confirmed that: A second medical use claim directed to a patient subgroup can be novel where the subgroup is physiologically or pathologically distinct and linked to a different therapeutic effect. An added...
As reported in our earlier update, the Paris Central Division concluded in May 2026 that the UPC could hear such an action where the patent was subsequently granted before the defence was filed. The Court of Appeal has now reached the same practical conclusion,...
Abbott is the proprietor of a patent describing a continuous glucose monitoring device and a method of assembling the same. SiBio provide devices for continuous ketone monitoring, and Abbott were concerned that they were about to launch a new product that would...
Background The Claimant, Agathon, was the proprietor of a European patent relating to a mechanical system designed to improve alignment in industrial machinery. Particularly, the invention concerns the repeated opening and closing of heavy metal components where...
Background Before the UPC opened its doors on 1 June 2023, many proprietors of European patents were wary of litigating their patents in an as-yet untested forum. To address these concerns, the authors of the UPC Agreement (“UPCA”) decided to implement a 7-year...
Background: Long-Arm Jurisdiction The Unified Patent Court (“UPC”) was introduced as a central forum for enforcing European patents across the European Union (“EU”). However, not all EU Member States (e.g. Spain) signed up to the UPC Agreement (“UPCA”), and some...
Recent Comments